Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Ichimaro, Yamada"'
Autor:
Yoshiyuki Nakayasu, Ichimaro Yamada, Fumitaka Suzuki, Hiromitsu Kumada, Madori Orihashi, Naohiro Kamiya
Publikováno v:
Hepatology Research. 47:514-521
Aim To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naive patients and relapsed patients compared to previous TVR-based triple therapy in Japan. Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fee78684af84280eb85358d2b9f3c48
https://doi.org/10.1111/hepr.12722
https://doi.org/10.1111/hepr.12722
Autor:
Yoshihisa Toda, Shinsuke Kaku, Shogo Kawabata, Miho Kamezawa, Masanori Sugimoto, Ichimaro Yamada, Noboru Otsuka, Hideo Matsumoto, Hiromi Endo
Publikováno v:
Pharmacology & Pharmacy. :305-312
We developed a novel topical non-steroidal anti-inflammatory drug (NSAID)patch, S(+)-flurbiprofen plaster, (SFPP), containing S(+)-flurbiprofen (SFP), an enantiomer of flurbiprofen (FP). In a previous study conducted in an animal model, we showed goo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::821c733207e5f0bb019a03372d06440b
https://doi.org/10.4236/pp.2016.78037
https://doi.org/10.4236/pp.2016.78037
Autor:
Yuichi Hoshino, Noboru Otsuka, Ichimaro Yamada, Isao Matsushita, Hideo Matsumoto, Kazuo Uebaba, Miho Kamezawa, Ikuko Yataba, Sigeru Sasaki
Publikováno v:
European Journal of Clinical Pharmacology
Purpose The purpose of this study is to investigate the pharmacokinetics and deep tissue penetration capability of the newly developed S-flurbiprofen plaster (SFPP) in humans. Methods Study 1: SFPP tape-type patch (2–60 mg) was applied to the lower
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93baed6e8f469971817aa8ff23de642c
http://europepmc.org/articles/PMC4701782
http://europepmc.org/articles/PMC4701782
Autor:
Hiromitsu Kumada, Kazuaki Chayama, Joji Toyota, Takeshi Okanoue, Ichimaro Yamada, Makoto Nakamuta, Tetsuo Takehara, Fumitaka Suzuki, Masatoshi Ishigami, Yoshiyuki Nakayasu, Miyoko Ochi, Ken Sato
Publikováno v:
Hepatology Research. 45:745-754
Aim This study assessed the efficacy and safety of telaprevir in combination with peginterferon-α-2b (PEG IFN) and ribavirin (RBV), for Japanese difficult-to-treat patients with hepatitis C virus (HCV) genotype 2 who had not achieved sustained virol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1557fdd2eb92e7ccca2f946a631329c9
https://doi.org/10.1111/hepr.12416
https://doi.org/10.1111/hepr.12416
Autor:
Katsuhisa Inoue, Kazuo Matsubara, Hiroyuki Kusuhara, Satohiro Masuda, Ken-ichi Inui, Tomoko Kito, Masayuki Suzuki, Yoshinori Moriyama, Noriko Hisanaga, Yasuhisa Adachi, Ichimaro Yamada, Tomohisa Nakada
Publikováno v:
Drug Metabolism and Pharmacokinetics. 29:266-271
Telaprevir-based triple therapy is a highly effective treatment for chronic hepatitis C. However, adverse reactions include reversible and dose-dependent elevation of serum creatinine levels. We speculated that this effect reflects inhibition of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b6ed17600ca7f2cab19d321f98d40b
https://doi.org/10.2133/dmpk.dmpk-13-rg-118
https://doi.org/10.2133/dmpk.dmpk-13-rg-118
Autor:
Itaru Ozeki, Namiki Izumi, Shinya Takahashi, Fumitaka Suzuki, Kazuaki Chayama, Y. Kawakami, Yoshiyasu Karino, Yasuhiro Asahina, Y. Suzuki, K. Aoki, Hiromitsu Kumada, Naohiro Kamiya, Ichimaro Yamada, Joji Toyota
Publikováno v:
Journal of Viral Hepatitis
Hepatitis C virus (HCV) subtype 1b, which infects approximately 70% of Japanese carriers, is likely to be more eradicable by a telaprevir regimen than subtype 1a because of the higher genetic barrier of Val(36) and Arg(155) substitutions. The aims of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7d59573e759427983724c08f09d7ee7
http://europepmc.org/articles/PMC3592988
http://europepmc.org/articles/PMC3592988
Autor:
Hiromitsu, Kumada, Fumitaka, Suzuki, Naohiro, Kamiya, Madori, Orihashi, Yoshiyuki, Nakayasu, Ichimaro, Yamada
Publikováno v:
Hepatology research : the official journal of the Japan Society of Hepatology. 47(6)
To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naïve patients and relapsed patients compared to previous TVR-based triple therapy in Japan.The stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5421c66fb599637b9b2073b72e113ebd
https://pubmed.ncbi.nlm.nih.gov/27062488
https://pubmed.ncbi.nlm.nih.gov/27062488
Autor:
Hiromitsu Kumada, Masahiro Kobayashi, Yasuji Arase, Mariko Kobayashi, Satoshi Saito, Keiji Aoki, Tetsuya Hosaka, Yoshiyuki Suzuki, Yoshiyuki Nakayasu, Sachiyo Watahiki, Kenji Ikeda, Norio Akuta, Fumitaka Suzuki, Hidetaka Tsuda, Rie Mineta, Yuya Seko, Ichimaro Yamada, Hitomi Sezaki, Yusuke Kawamura
Publikováno v:
Hepatology Research. 43:691-701
Aim The aims of this study are to assess the antiviral effects, safety and telaprevir (TVR) pharmacokinetics in two cohorts given TVR every 8 h (q8h) at doses of 500 mg and 750 mg with peginterferon-α-2b and ribavirin in chronic hepatitis C patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::301b398d24ec5f1d323efdbd19e96576
https://doi.org/10.1111/hepr.12009
https://doi.org/10.1111/hepr.12009
Autor:
Fumitaka Suzuki, H Matsui, Y Sakurai, M Kano, H Kumada, K. Aoki, Ichimaro Yamada, Naohiro Kamiya
Publikováno v:
Journal of Viral Hepatitis
Summary. Background: Telaprevir in combination with peginterferon and ribavirin is a promising advancement in chronic hepatitis C treatment. However, the safety, tolerability, pharmacokinetics and antiviral profiles of telaprevir alone beyond 2 weeks
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b51e56ddb1b78739cdd72842409c69c5
http://europepmc.org/articles/PMC3584515
http://europepmc.org/articles/PMC3584515
Autor:
Toshiya Inaba, Hirotaka Matsui, Mayu Onishi, Shoichi Takahashi, Eiji Iwao, C. Nelson Hayes, Ichimaro Yamada, Tomohiko Kono, Naohiro Kamiya, Akinori Kanai, Kazuaki Chayama, Michio Imamura, Katsutoshi Yoshizato, Hidenori Ochi, Nobuhiko Hiraga, Hiromi Abe, Chise Tateno, Masataka Tsuge, Shinji Tanaka
Publikováno v:
Hepatology. 54:781-788
Telaprevir is a potent inhibitor of hepatitis C virus (HCV) NS3-4A protease. However, the emergence of drug-resistant strains during therapy is a serious problem, and the susceptibility of resistant strains to interferon (IFN), as well as the details
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a7a809085bff011ffd9d7fda7db83ac
https://doi.org/10.1002/hep.24460
https://doi.org/10.1002/hep.24460